Logo image of CRL

CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis

NYSE:CRL - New York Stock Exchange, Inc. - US1598641074 - Common Stock - Currency: USD

106.05  +1.8 (+1.73%)

After market: 106.04 -0.01 (-0.01%)

Fundamental Rating

4

CRL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. CRL has an average financial health and profitability rating. CRL has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year CRL was profitable.
In the past year CRL had a positive cash flow from operations.
Each year in the past 5 years CRL has been profitable.
In the past 5 years CRL always reported a positive cash flow from operatings.
CRL Yearly Net Income VS EBIT VS OCF VS FCFCRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

1.2 Ratios

CRL has a Return On Assets of 0.14%. This is in the better half of the industry: CRL outperforms 67.86% of its industry peers.
With a decent Return On Equity value of 0.30%, CRL is doing good in the industry, outperforming 69.64% of the companies in the same industry.
The Return On Invested Capital of CRL (6.66%) is better than 73.21% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CRL is significantly below the industry average of 12.38%.
Industry RankSector Rank
ROA 0.14%
ROE 0.3%
ROIC 6.66%
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
CRL Yearly ROA, ROE, ROICCRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

Looking at the Profit Margin, with a value of 0.25%, CRL is in the better half of the industry, outperforming 67.86% of the companies in the same industry.
CRL's Profit Margin has declined in the last couple of years.
CRL's Operating Margin of 13.60% is fine compared to the rest of the industry. CRL outperforms 73.21% of its industry peers.
In the last couple of years the Operating Margin of CRL has remained more or less at the same level.
Looking at the Gross Margin, with a value of 34.76%, CRL is doing worse than 64.29% of the companies in the same industry.
CRL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.6%
PM (TTM) 0.25%
GM 34.76%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
CRL Yearly Profit, Operating, Gross MarginsCRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

More info and screens

4

2. Health

2.1 Basic Checks

CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for CRL has been reduced compared to 1 year ago.
The number of shares outstanding for CRL has been increased compared to 5 years ago.
CRL has a better debt/assets ratio than last year.
CRL Yearly Shares OutstandingCRL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CRL Yearly Total Debt VS Total AssetsCRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

CRL has an Altman-Z score of 1.95. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
CRL has a Altman-Z score of 1.95. This is comparable to the rest of the industry: CRL outperforms 55.36% of its industry peers.
CRL has a debt to FCF ratio of 4.47. This is a neutral value as CRL would need 4.47 years to pay back of all of its debts.
CRL has a Debt to FCF ratio of 4.47. This is in the better half of the industry: CRL outperforms 73.21% of its industry peers.
A Debt/Equity ratio of 0.65 indicates that CRL is somewhat dependend on debt financing.
CRL has a Debt to Equity ratio of 0.65. This is in the lower half of the industry: CRL underperforms 71.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.47
Altman-Z 1.95
ROIC/WACC0.67
WACC10.01%
CRL Yearly LT Debt VS Equity VS FCFCRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

A Current Ratio of 1.41 indicates that CRL should not have too much problems paying its short term obligations.
The Current ratio of CRL (1.41) is worse than 75.00% of its industry peers.
CRL has a Quick Ratio of 1.13. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
CRL has a Quick ratio of 1.13. This is in the lower half of the industry: CRL underperforms 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.13
CRL Yearly Current Assets VS Current LiabilitesCRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CRL have decreased by -3.10% in the last year.
Measured over the past years, CRL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.93% on average per year.
CRL shows a decrease in Revenue. In the last year, the revenue decreased by -1.92%.
The Revenue has been growing by 9.09% on average over the past years. This is quite good.
EPS 1Y (TTM)-3.1%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%8.13%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-1.08%

3.2 Future

Based on estimates for the next years, CRL will show a small growth in Earnings Per Share. The EPS will grow by 5.70% on average per year.
CRL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.74% yearly.
EPS Next Y-8.71%
EPS Next 2Y-0.79%
EPS Next 3Y3.03%
EPS Next 5Y5.7%
Revenue Next Year-5.23%
Revenue Next 2Y-0.52%
Revenue Next 3Y1.65%
Revenue Next 5Y3.74%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CRL Yearly Revenue VS EstimatesCRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
CRL Yearly EPS VS EstimatesCRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 5 10 15 20 25

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 10.28, the valuation of CRL can be described as reasonable.
Based on the Price/Earnings ratio, CRL is valued cheaper than 96.43% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.29. CRL is valued rather cheaply when compared to this.
CRL is valuated reasonably with a Price/Forward Earnings ratio of 11.26.
Based on the Price/Forward Earnings ratio, CRL is valued cheaply inside the industry as 96.43% of the companies are valued more expensively.
CRL's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.08.
Industry RankSector Rank
PE 10.28
Fwd PE 11.26
CRL Price Earnings VS Forward Price EarningsCRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CRL is valued cheaper than 100.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 96.43% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 10.38
EV/EBITDA 7.95
CRL Per share dataCRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)1.15
EPS Next 2Y-0.79%
EPS Next 3Y3.03%

More info and screens

0

5. Dividend

5.1 Amount

CRL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHARLES RIVER LABORATORIES

NYSE:CRL (4/17/2025, 8:10:54 PM)

After market: 106.04 -0.01 (-0.01%)

106.05

+1.8 (+1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-19 2025-02-19/bmo
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners105.79%
Inst Owner Change1.84%
Ins Owners0.83%
Ins Owner Change1.05%
Market Cap5.21B
Analysts63.33
Price Target180.54 (70.24%)
Short Float %5.82%
Short Ratio2.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.86%
Min EPS beat(2)4.03%
Max EPS beat(2)5.7%
EPS beat(4)4
Avg EPS beat(4)8.54%
Min EPS beat(4)4.03%
Max EPS beat(4)15.8%
EPS beat(8)8
Avg EPS beat(8)7.07%
EPS beat(12)12
Avg EPS beat(12)5.74%
EPS beat(16)16
Avg EPS beat(16)6.05%
Revenue beat(2)2
Avg Revenue beat(2)1.67%
Min Revenue beat(2)0.91%
Max Revenue beat(2)2.43%
Revenue beat(4)3
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-0.86%
Max Revenue beat(4)2.43%
Revenue beat(8)6
Avg Revenue beat(8)1.15%
Revenue beat(12)8
Avg Revenue beat(12)0.97%
Revenue beat(16)11
Avg Revenue beat(16)0.99%
PT rev (1m)-2.62%
PT rev (3m)-18.02%
EPS NQ rev (1m)-1.23%
EPS NQ rev (3m)-12.86%
EPS NY rev (1m)-2.55%
EPS NY rev (3m)-8.99%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)-4.85%
Revenue NY rev (1m)-0.31%
Revenue NY rev (3m)-6.36%
Valuation
Industry RankSector Rank
PE 10.28
Fwd PE 11.26
P/S 1.29
P/FCF 10.38
P/OCF 7.09
P/B 1.5
P/tB N/A
EV/EBITDA 7.95
EPS(TTM)10.32
EY9.73%
EPS(NY)9.42
Fwd EY8.88%
FCF(TTM)10.21
FCFY9.63%
OCF(TTM)14.95
OCFY14.1%
SpS82.45
BVpS70.47
TBVpS-2.21
PEG (NY)N/A
PEG (5Y)1.15
Profitability
Industry RankSector Rank
ROA 0.14%
ROE 0.3%
ROCE 8.43%
ROIC 6.66%
ROICexc 6.86%
ROICexgc 15.71%
OM 13.6%
PM (TTM) 0.25%
GM 34.76%
FCFM 12.39%
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexcg growth 3Y-14.69%
ROICexcg growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score6
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.47
Debt/EBITDA 2.45
Cap/Depr 64.4%
Cap/Sales 5.75%
Interest Coverage 4.46
Cash Conversion 80.5%
Profit Quality 4871.42%
Current Ratio 1.41
Quick Ratio 1.13
Altman-Z 1.95
F-Score6
WACC10.01%
ROIC/WACC0.67
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.1%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%8.13%
EPS Next Y-8.71%
EPS Next 2Y-0.79%
EPS Next 3Y3.03%
EPS Next 5Y5.7%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-1.08%
Revenue Next Year-5.23%
Revenue Next 2Y-0.52%
Revenue Next 3Y1.65%
Revenue Next 5Y3.74%
EBIT growth 1Y-15.66%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year27.88%
EBIT Next 3Y14.43%
EBIT Next 5Y11.83%
FCF growth 1Y37.29%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y7.41%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%